Although, Palbociclib (PD 0332991) has been approved by the US Food and Drug Administration (FDA) on February 3, 2015 as a first-line medicine for advanced post-menopausal ER+, HER2-negative breast cancer, used in combination with letrozole (9). This evidence concerns the gene ESR1 and breast carcinoma.